dc.contributor.author |
MacDonald, HJ |
en |
dc.contributor.author |
Stinear, Cathy |
en |
dc.contributor.author |
Ren, A |
en |
dc.contributor.author |
Coxon, JP |
en |
dc.contributor.author |
Kao, J |
en |
dc.contributor.author |
Macdonald, L |
en |
dc.contributor.author |
Snow, B |
en |
dc.contributor.author |
Cramer, SC |
en |
dc.contributor.author |
Byblow, Winston |
en |
dc.date.accessioned |
2016-10-25T03:47:09Z |
en |
dc.date.issued |
2016-07 |
en |
dc.identifier.citation |
Journal of Cognitive Neuroscience, 2016, 28 (7), 909 - 919 |
en |
dc.identifier.issn |
0898-929X |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/30847 |
en |
dc.description.abstract |
Dopamine agonists can impair inhibitory control and cause impulse control disorders for those with Parkinson disease (PD), although mechanistically this is not well understood. In this study, we hypothesized that the extent of such drug effects on impulse control is related to specific dopamine gene polymorphisms. This double-blind, placebo-controlled study aimed to examine the effect of single doses of 0.5 and 1.0 mg of the dopamine agonist ropinirole on impulse control in healthy adults of typical age for PD onset. Impulse control was measured by stop signal RT on a response inhibition task and by an index of impulsive decision-making on the Balloon Analogue Risk Task. A dopamine genetic risk score quantified basal dopamine neurotransmission from the influence of five genes: catechol-O-methyltransferase, dopamine transporter, and those encoding receptors D1, D2, and D3. With placebo, impulse control was better for the high versus low genetic risk score groups. Ropinirole modulated impulse control in a manner dependent on genetic risk score. For the lower score group, both doses improved response inhibition (decreased stop signal RT) whereas the lower dose reduced impulsiveness in decision-making. Conversely, the higher score group showed a trend for worsened response inhibition on the lower dose whereas both doses increased impulsiveness in decision-making. The implications of the present findings are that genotyping can be used to predict impulse control and whether it will improve or worsen with the administration of dopamine agonists. |
en |
dc.description.uri |
https://www.ncbi.nlm.nih.gov/pubmed/26942320 |
en |
dc.format.medium |
Print-Electronic |
en |
dc.language |
English |
en |
dc.publisher |
Massachusetts Institute of Technology |
en |
dc.relation.ispartofseries |
Journal of cognitive neuroscience |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0898-929X/
http://www.mitpressjournals.org/page/policies/authorposting |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.title |
Dopamine Gene Profiling to Predict Impulse Control and Effects of Dopamine Agonist Ropinirole |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1162/jocn_a_00946 |
en |
pubs.issue |
7 |
en |
pubs.begin-page |
909 |
en |
pubs.volume |
28 |
en |
dc.identifier.pmid |
26942320 |
en |
pubs.author-url |
http://cognet.mit.edu/journal/10.1162/jocn_a_00946 |
en |
pubs.end-page |
919 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
524991 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
School of Medicine |
en |
pubs.org-id |
Medicine Department |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Exercise Sciences |
en |
dc.identifier.eissn |
1530-8898 |
en |
pubs.record-created-at-source-date |
2016-10-25 |
en |
pubs.dimensions-id |
26942320 |
en |